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Myocardial Bridging in Adult and Pediatric
Patients With Hypertrophic Cardiomyopathy
Is Not Associated With Poor Outcome
The recent report by Sorajja et al. (1) that myocardial bridging in
adults with hypertrophic cardiomyopathy (HCM) is not associated
with an increased risk of sudden death is in agreement with our
own study conducted in children (2), and is in contrast to the
suggestion that systolic coronary compression in pediatric patients
results in myocardial ischemia and a poor prognosis (3).
Unfortunately, Sorajja et al. (1) misrepresent our findings. They
include our study with references that have associated myocardial
bridging with “nuclear perfusion abnormalities, chest pain, ven-
tricular tachycardia and an increased risk of sudden cardiac death.”
Our conclusions were directly the opposite: we found no associa-
tion between coronary bridging, symptoms, perfusion abnormali-
ties, ventricular arrhythmias, and sudden death. Rather, in multi-
variate analyses, perfusion abnormalities were related to the
magnitude of left ventricular hypertrophy (LVH) and the presence
of septal artery compression. Unfortunately, Sorajja et al. did not
evaluate angiograms for septal artery compression, and the associ-
ation between bridging and severity of LVH is not assessed in
patient groups of similar age. Finally, our study was conducted in
a group of 57 pediatric patients, and not in only 23 as stated in the
current report.
The report by Sorajja et al. emphasizes our conclusions that it is
very unlikely that systolic compression of epicardial coronary
arteries results in poorer outcome in HCM, and that there is
currently no rationale for surgical or catheter-based correction (2).
The contribution made by septal artery compression, intraventric-
ular pressure, and LVH to perfusion abnormalities and therefore to
symptoms and prognosis should be the focus of further investiga-
tion.
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REPLY
We appreciate the interest of Drs. Mohiddin and Fananapazir in
our recent publication on myocardial bridging in adult patients
with hypertrophic cardiomyopathy (HCM) (1). We apologize for
any misrepresentation of the data from their publication on
myocardial bridging in pediatric patients with HCM (2). The
study published by Mohiddin et al. was included in the list of
references that associated bridging with perfusion abnormalities, as
their study had demonstrated such an association in univariate
analyses. We emphasized the absence of this relation, in their
study, after adjustment for other clinical variables in order to
support our conclusions that bridging is not associated with an
adverse prognosis.
Septal artery compression was not examined in our study.
However, it is unlikely that this finding would be associated with
adverse outcomes as such compression is found in nearly all
patients with epicardial bridging, and there were no differences
with respect to ventricular tachycardia or prognosis in the inves-
tigators’ study (2). We observed no difference in maximal left
ventricular wall thickness between patients with and without
bridging. Finally, the study by Drs. Mohiddin and Fananapazir did
examine 57 pediatric HCM patients, of whom 23 had myocardial
bridging. We apologize for this typographical error.
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Embolic Complications in
Streptococcus Viridans Endocarditis
In their editorial, entitled “Toward reducing embolic complica-
tions from endocarditis,” Drs. Homma and Grahame-Clarke
indicated that the type of the organism may increase the likelihood
of embolization and that Streptococcus viridans and Staphylococcus
aureus endocarditis are associated with higher incidence of embo-
lization (1). Though this is correct for S. aureus endocarditis, S.
viridans endocarditis is not specifically associated with higher
incidence of embolization (2,3). McLeod et al. (2), Cherubin et al.
(3), and Utley et al. (4,5) found the highest incidence of emboli
with fungus infection (60% to 100%), S. aureus (58%), and
Neisseria (35%). Streptococcus species, including viridans, and
enterococci had a lower risk of embolization (15% to 25%). In their
editorial, Homma and Grahame-Clarke quoted De Castro et al.
for higher embolization in S. viridans (6). However, De Castro et
al. showed in their series that only 6 out of 22 patients with
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Streptococci had embolization, in contrast to 11 out of 16 patients
with S. aureus endocarditis.
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We thank Dr. Mansi for his comments and welcome the chance to
summarize the literature on this subject. Older studies published
prior to 1980 showed a high percentage of those with Staphylo-
coccal endocarditis sustaining embolic or neurological complica-
tions; however, no statistical comparisons with other organisms
were made (1–3). For the most part, recent studies have reported
no significant difference in the incidence of embolization among
different underlying infective organisms (4–9). However, two of
these studies did show a higher rate of embolic complications in
cases caused by Staphylococcus aureus as compared to Streptococcus
viridans (8,9). A large series of patients with left-sided endocarditis
showed that overall S. aureus endocarditis had an embolic rate
2.4-fold greater than that with S. viridans endocarditis (10). Other
investigators have reported a significant association between
Staphylococcal endocarditis and embolization in cases selected by
transesophageal echocardiography (11), where all neurological
complications were considered together (12,13), or where intra-
cranial hemorrhage alone was considered (14). Also, although the
reported incidence of embolization in fungal and enterococcal
endocarditis is high, numbers in any given series are small
(1–3,15).
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A Randomized Trial of Aspirin
on the Risk of Embolic Events
in Patients With Infective Endocarditis
We read with great interest the study by Chan et al. (1). We are
not surprised that high-dose aspirin (325 mg once daily) was not
beneficial in patients with infective endocarditis and caused exces-
sive bleeding. First, the dose of aspirin that has optimal benefits
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